Okubo M, Chen X M, Kamata K, Masaki Y, Uchiyama T
Transplantation. 1986 Apr;41(4):495-8. doi: 10.1097/00007890-198604000-00016.
The mode of action of mizoribine (MZR) as a B cell inhibitor was studied using DBA/2 mice. Its in vitro administration significantly delayed the primary response in hemagglutinin production against sheep erythrocytes by suppressing the IgM antibody formation. In vitro plaque-forming cell (PFC) response against both T-dependent and T-independent antigens, such as TNP-SRBC and TNP-Brucella abortus, was dose-dependently suppressed by MZR. Since PFC formation by the T-depleted fraction of splenocytes was likewise suppressed, MZR may inhibit humoral antibody response by directly affecting the B cells (and/or macrophages) as well as by modulating the regulatory T cells. MZR may only act on a certain stage of the cell cycle of B lymphocytes following antigenic stimulation. It may not interfere with the initial antigen recognition or with mature B cells.
使用DBA/2小鼠研究了咪唑立宾（MZR）作为B细胞抑制剂的作用模式。其体外给药通过抑制IgM抗体形成，显著延迟了针对绵羊红细胞的血凝素产生的初次反应。MZR剂量依赖性地抑制了针对T细胞依赖性和T细胞非依赖性抗原（如TNP-SRBC和TNP-流产布鲁氏菌）的体外空斑形成细胞（PFC）反应。由于脾细胞T细胞耗竭部分的PFC形成同样受到抑制，MZR可能通过直接影响B细胞（和/或巨噬细胞）以及调节调节性T细胞来抑制体液抗体反应。MZR可能仅作用于抗原刺激后B淋巴细胞细胞周期的特定阶段。它可能不会干扰初始抗原识别或成熟B细胞。
